Neurotensin (NT) has been proposed as an endogenous antipsychotic based in part on the similarity in behavioural effects to antipsychotic drugs, for example, attenuation of both amphetamine-induced hyperlocomotion (AH) and amphetamine disrupted pre-pulse inhibition in the rat. However, there is some evidence that repeated administration of NT or an analogue produces behavioural tolerance to such effects. The present experiments sought to confirm and extend these findings by testing the effects on AH of 7 days central administration of NT and the NT 1 selective analogue PD 149163 and the effects of 21 days central administration of NT. NT and PD149163 continuously administered for 7 days produced no effect on AH (in contrast to attenuation with a single injection here and previously reported), whereas 21 days of NT administration potentiated AH. Together, these studies report that the effects of NT or a NT analogue on AH depends on the duration of administration of peptide. The results are discussed in comparison with the reported antipsychotic properties of acute administration of NT and possible mechanisms involving NT1 receptors.
Arnt, J. (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol283: 55-62.
2.
Binder, EB, Gross, RE, Nemeroff, CB, Kilts, CD (2002) Effects of NT receptor antagonism on latent inhibition in Sprague-Dawley rats. Psychopharmacology161: 288A-295A.
3.
Binder, EB, Kinkead, B., Owens, MJ, Nemeroff, CB (2000) The role of NT in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol Psychiatry50: 856-872.
Bissette, G., Nemeroff, CB, Loosen, PT, Prange, AJ, Lipton, MA (1976) Hypothermia and intolerance to cold induced administration of the hypothalamic peptide NT. Nature262: 607-609.
6.
Boules, M., McMahon, B., Wang, R., Warrington, L., Stewart, J., Yerbury, S., Faug, A., McCormack, D., Richelson, E. (2003) Selective tolerance to the hypothermic effects of a NT analog that crosses the blood-brain barrier. Brain Res987: 39-48.
7.
Boules, M., Warrington, L., Fauq, A., McCormick, D., Richelson, E. (2001) A novel NT analog blocks cocaine and D-amphetamine-induced hyperactivity. Eur J Pharmacol426: 73-76.
8.
Caceda, R., Kinkead, B., Owens, MJ, Nemeroff, CB (2005) Virally mediated increased NT 1 receptor in the nucleus accumbens decreases behavioral effects of mesolimbic system activation . J Neurosci25: 11748-11756.
9.
Carraway, R., Leeman, SE (1973) The isolation of a new hypotensive peptide, NT, from bovine hypothalami. J Biol Chem248: 6854- 6861.
Donatodi Paola, E., Cusack, B., Yamada, M., Richelson, E. (1993) Desensitization and down-regulation of NT receptors in murine neuroblastoma clone N1E-115 by [D-Lys8] NT (8-13). J Pharmacol Exp Ther264: 1-5.
12.
Ervin, GN, Birkemo, LS, Nemeroff, CB, Prange, AJ (1981) Neurotensin blocks certain amphetamine induced behaviours. Nature291: 73-76.
13.
Feifel, D., Minor, KL, Dulawa, S., Swerdlow, NR (1997a) The effects of intra-accumbens NT on sensorimotor gating. Brain Res760: 80- 84.
14.
Feifel, D., Reza, TL, Roebeck, SL (1997b) Pro-dopaminergic effects of NT on sensori motor gating deficits. Peptides18: 1457-1460.
15.
Feifel, D., Reza, TL, Wustrow, DJ, Davis, MD (1999) Novel antipsychotic-like effects on pre-pulse inhibition of startle produced by a NT agonist. J Pharmacol Exp Ther288: 710-713.
16.
Hadden, MK, Orwig, KS, Kokko, KP, Mazella, J., Dix, TA (2005) Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable NT (8-13) analogues containing non-natural arginine and lysine residues. Neuropharmacology49: 1149-1159.
17.
Hermans, E., Vanisberg, MA, Geurts, M., Maloteaux, M. (1997) Down-regulation of NT receptors after ligand-induced internalization in rat primary cultured neurons. Neurochem Int31: 291-299.
18.
Hertel, P., Byskov, L., Didriksen, M., Arnt, J. (2001). Induction of tolerance to the suppressant effect of NT analog NT69L on amphetamine-induced hyperactivity. Eur J Pharmacol422: 77-81.
19.
Hertel, P., Olsen, CK, Didriksen, M., Arnt, J. (2002) Repeated administration of the NT analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour . Eur J Pharmacol439: 107-111.
20.
Holtom, PE, Needham, PL, Bennett, GW, Aspley, S. (2000a) Neurotensin: controversial findings on its neuromodulatory role in the mesolimbic dopamine system. Schizophr Res41: 239-239.
21.
Holtom, PE, Wasuntararawat, C., Moss, SH, Aspley, S., Needham, PL, Bennett, GW (2000b). A highly sensitive and selective radioimmunoassay for the measurement of NT. J Neurosci Methods100: 151- 156.
22.
Jolicoeur, FB, Barbeau, A., Rioux, F., Quirion, R., St-Pierre, S. (1981). Differential neurobehavioral effects of NT and structural analogues. Peptides2: 171-175.
23.
Kinkead, B., Shahid, S., Owens, M., Nemeroff, CB (2000) Effects of acute and subchronic administration of typical and atypical antipyschotic drugs on the NT system of the rat brain . J Pharmacol Exp Ther295: 67-73.
24.
Kitabi, P., De Nadai, F., Labbe-Jullie, C., Dubuc, I., Nouel, D., Costentin, J., Masuo, Y., Rostene, W., Woulfe, J., Lafortune, L. (1992) Functional and pharmacological aspects of central neuropeptidergic transmission mediated by NT and neuromedin. Clin Neuropharmacol15(Suppl. 1A,11): 313A-314A.
25.
Lambert, PD, Gross, R., Nemeroff, CB, Kilts, CD (1995) Anatomy and mechanisms of NT-dopamine interactions in the central nervous system. Ann NY Acad Sci757: 377-389.
26.
Leonetti, M., Brun, P., Clerget, M., Steinberg, R., Soubrie, P., Renaud, B., Suaud-Chagny, MF (2004) Specific involvement of NT type 1 receptor in the NT-mediated in vivo dopamine efflux using knockout mice. J Neurochem89: 1-6.
27.
Lindstrom, LH, Widerlov, E., Bissette, G., Nemeroff, CB (1988) Reduced CSF NT concentration in drug free schizophrenic patients. Schizophr Res1: 55-59.
28.
Ljungberg, T., Ungerstedt, U. (1976) Automatic registration of behaviour related to dopamine and noradrenaline transmission. Eur J Pharmacol36: 181-188.
Nemeroff, CB, Luttinger, DE, Hernadnez, RB (1983) Interactions of NT with brain dopamine systems: biochemical and behavioral Studies. J Pharmacol Exp Ther225: 337-345.
31.
Norman, C., Beckett, SRG, Roe, CH, Ashton, D., Nayak, S., Bennett, GW (2004) Reciprocal effects of acute versus chronic central administration of NT on amphetamine hyperactivity. J Psychopharmacol18: A56-A56.
32.
Norman, C., Beckett, SRG, Spicer, CH, Ashton, D., Langlois, X., Bennett, GW (2005) Effects of NT and NT analogues on amphetamine-induced hyperlocomotion; antipsychotic or psychotomimetic?J Psychopharmacol19(Suppl.): A30-A30.
33.
Petrie, KA, Bubser, M., Casey, CD, Davis, MD, Roth, BL, Deutch, AY (2004) The NT agonist PD 149163 increases Fos expression in the prefrontal cortex of the rat. Neuropsychopharmacology29: 1878-1888.
34.
Robinson, TE, Becker, JB (1986) Enduring changes in brain and behaviour produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev11: 157-198.
35.
Rompré, PP (1997) Repeated activation of NT receptors sensitises to the stimulant effect of amphetamine. Eur J Pharmacol328: 131- 134.
36.
Rostene, W., Brouard, A., Dana, C., Masuo, Y., Agid, F., Vial, M., Lhiaubet, AM, Pelaprat, D. (1992) Interaction between NT and dopamine in the brain. Morphofunctional and clinical evidence. Ann NY Acad Sci668: 365-367.
37.
Sharma, RP, Janicak, PG, Bissette, G., Nemeroff, CB (1997) CSF NT concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am J Psychiatry29: 1019-1021.
38.
Shilling, PD, Richelson, E., Feifel, D. (2003) The effects of systemic NT69L, a NT agonist on baseline and drug-disrupted prepulse inhibition. Behav Brain Res143: 7-14.
39.
Wustrow, DJ, Davies, MD, Akunne, HC, Corbin, AE, Wiley, JN, Wise, LD, Heffner, TG (1995) Reduced amide bond NT 8-13 mimetics with potent in vivo activity. Bioorg Med Chem Lett5: 999-1002.
